Remnant-like lipoproteins, hormone therapy, and angiographic and clinical outcomes: the Women's Angiographic Vitamin & Estrogen Trial.

[1]  T. Rabelink,et al.  Treatment with hormone replacement therapy lowers remnant lipoprotein particles in healthy postmenopausal women: results from a randomized trial , 2003, European journal of clinical investigation.

[2]  J. Hsia,et al.  Women's angiographic vitamin and estrogen trial: design and methods. , 2002, Controlled clinical trials.

[3]  J. Hsia,et al.  Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. , 2002, JAMA.

[4]  Y. Sakai,et al.  Possible Relationship between Insulin Resistance and Remnant‐Like Lipoprotein Particles in Coronary Endothelial Dysfunction , 2002, Clinical cardiology.

[5]  C. Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[6]  Deborah Grady,et al.  Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). , 2002, JAMA.

[7]  R. Krauss,et al.  Properties of triglyceride-rich and cholesterol-rich lipoproteins in the remnant-like particle fraction of human blood plasma. , 2002, Journal of lipid research.

[8]  K. Kugiyama,et al.  Comparison of remnant-like lipoprotein particles in postmenopausal women with and without coronary artery disease and in men with coronary artery disease. , 2001, The American journal of cardiology.

[9]  A. Yonemura,et al.  Remnant-like particles cholesterol is higher in diabetic patients with coronary artery disease. , 2001, Metabolism: clinical and experimental.

[10]  E. Schaefer,et al.  Comparison of fasting and postprandial plasma lipoproteins in subjects with and without coronary heart disease. , 2001, The American journal of cardiology.

[11]  M. Nieminen,et al.  Remnant-like lipoprotein particle cholesterol concentration and progression of coronary and vein-graft atherosclerosis in response to gemfibrozil treatment. , 2001, Atherosclerosis.

[12]  A. Wakatsuki,et al.  Estrogen-induced small low density lipoprotein particles may be atherogenic in postmenopausal women. , 2001, Journal of the American College of Cardiology.

[13]  D. Reboussin,et al.  Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. , 2000, The New England journal of medicine.

[14]  K. Nakajima,et al.  Relation between RLP-triglyceride to RLP-cholesterol ratio and particle size distribution in RLP-cholesterol profiles by HPLC. , 2000, Clinica chimica acta; international journal of clinical chemistry.

[15]  H. Masuoka,et al.  Association of remnant-like particle cholesterol with coronary artery disease in patients with normal total cholesterol levels. , 2000, American heart journal.

[16]  M. Sanada,et al.  The effect of hormone replacement therapy on metabolism of lipoprotein remnants in postmenopausal women. , 2000, Maturitas.

[17]  J. Davignon,et al.  Detection, quantification, and characterization of potentially atherogenic triglyceride-rich remnant lipoproteins. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[18]  H Yasue,et al.  Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. , 1999, Circulation.

[19]  K. Nakajima,et al.  Association of plasma triglyceride-rich lipoprotein remnants with coronary atherosclerosis in cases of sudden cardiac death. , 1999, Atherosclerosis.

[20]  T. Inoue,et al.  Impaired endothelium-dependent acetylcholine-induced coronary artery relaxation in patients with high serum remnant lipoprotein particles. , 1998, Atherosclerosis.

[21]  H. Masuoka,et al.  Predictive value of remnant-like particles cholesterol/high-density lipoprotein cholesterol ratio as a new indicator of coronary artery disease. , 1998, American heart journal.

[22]  P. Wilson,et al.  Remnant lipoprotein cholesterol and triglyceride reference ranges from the Framingham Heart Study. , 1998, Clinical chemistry.

[23]  M. Nieminen,et al.  Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. , 1997, Circulation.

[24]  S. Azen,et al.  Triglyceride‐ and Cholesterol‐Rich Lipoproteins Have a Differential Effect on Mild/Moderate and Severe Lesion Progression as Assessed by Quantitative Coronary Angiography in a Controlled Trial of Lovastatin , 1994, Circulation.

[25]  D H Blankenhorn,et al.  Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors. , 1990, Circulation.

[26]  E. Barrett-Connor,et al.  Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. , 1987, Circulation.

[27]  R. Blumenthal,et al.  Heart and estrogen/progestin replacement study follow-up (HERS-II) 1. Cardiovascular outcomes during 6.8 years of hormone therapy , 2002 .

[28]  P. Wilson,et al.  Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study. , 2001, Atherosclerosis.

[29]  A. Hamsten,et al.  Remnant lipoproteins are related to intima-media thickness of the carotid artery independently of LDL cholesterol and plasma triglycerides. , 2001, Journal of lipid research.